购物车
- 全部删除
- 您的购物车当前为空
Enavatuzumab (PDL192; ABT-361)为一种人源化IgG1单克隆抗体,专门靶向TNF样细胞凋亡弱诱导剂受体(TWEAK)。TWEAK是TWEAK受体(TweakR)的自然配体,能激活多种细胞反应。Enavatuzumab通过激活TweakR信号和促进抗体依赖性细胞介导的细胞毒性(ADCC),有效抑制肿瘤生长,并能招募骨髓效应细胞,进而消灭肿瘤细胞。该药物已在体外及体内实验中证实,能够抑制多种TweakR阳性的人类癌细胞系与异种移植瘤的增长。
Enavatuzumab (PDL192; ABT-361)为一种人源化IgG1单克隆抗体,专门靶向TNF样细胞凋亡弱诱导剂受体(TWEAK)。TWEAK是TWEAK受体(TweakR)的自然配体,能激活多种细胞反应。Enavatuzumab通过激活TweakR信号和促进抗体依赖性细胞介导的细胞毒性(ADCC),有效抑制肿瘤生长,并能招募骨髓效应细胞,进而消灭肿瘤细胞。该药物已在体外及体内实验中证实,能够抑制多种TweakR阳性的人类癌细胞系与异种移植瘤的增长。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5 mg | 询价 | 期货 |
产品描述 | Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody designed to target the TWEAK receptor (TweakR), a protein involved in various cellular responses through its interaction with its natural ligand, TWEAK (Fn14; TNFRSF12A). By directly engaging TweakR signaling and promoting antibody-dependent cell-mediated cytotoxicity (ADCC), enavatuzumab effectively inhibits tumor growth. It also recruits and activates myeloid effector cells to destroy tumor cells. Enavatuzumab has demonstrated the ability to suppress the proliferation of a range of human TweakR-positive cancer cell lines and tumorigenic models both in vitro and in vivo [1] [2]. |
CAS No. | 1062149-33-0 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 years | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.